FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3085262751> ?p ?o ?g. }

• W3085262751 endingPage "3752" @default.
• W3085262751 startingPage "3743" @default.
• W3085262751 abstract "PURPOSE Adjuvant trastuzumab monotherapy has not been compared with trastuzumab + chemotherapy. We investigated the relative value of trastuzumab monotherapy for older patients with breast cancer. METHODS This study was an open-label, randomized controlled study with a treatment selection design in which a noninferiority criterion was predefined. Patients aged 70-80 years with surgically treated human epidermal growth factor receptor 2–positive invasive breast cancer received trastuzumab monotherapy or trastuzumab + chemotherapy. The primary end point was disease-free survival (DFS) with assessment of prespecified hazard ratio (HR), relapse-free survival (RFS), adverse events (AEs), health-related quality of life (HRQoL), and restricted mean survival time (RMST). RESULTS The study involved 275 patients (mean age, 73.5 years) who were followed up for a mean of 4.1 years (range, 0.3-8.0 years). The percentages of patients by cancer stage were as follows: I (pT > 0.5 cm), 43.6%; IIA, 41.7%; IIB, 13.5%; and IIIA, 1.1%. Three-year DFS was 89.5% with trastuzumab monotherapy versus 93.8% with trastuzumab + chemotherapy (HR, 1.36; 95% CI, 0.72 to 2.58; P = .51). At 3 years, RMST differed by −0.39 months between arms (95% CI, −1.71 to 0.93; P = .56). Three-year RFS was 92.4% with trastuzumab monotherapy versus 95.3% with trastuzumab + chemotherapy (HR, 1.33; 95% CI, 0.63 to 2.79; P = .53). Common AEs were anorexia (7.4% v 44.3%; P < .0001) and alopecia (2.2% v 71.7%; P < .0001), and grade 3/4 nonhematologic AEs occurred in 11.9% versus 29.8% ( P = .0003) for trastuzumab monotherapy versus trastuzumab + chemotherapy, respectively. Clinically meaningful HRQoL deterioration rate showed significant differences at 2 months (31% for trastuzumab monotherapy v 48% for trastuzumab + chemotherapy; P = .016) and at 1 year (19% v 38%; P = .009). CONCLUSION The primary objective of noninferiority for trastuzumab monotherapy was not met. However, the observed loss of survival without chemotherapy was < 1 month at 3 years. Therefore, and in light of the lower toxicity and more favorable HRQoL profile, trastuzumab monotherapy can be considered an adjuvant therapy option for selected older patients." @default.
• W3085262751 created "2020-09-21" @default.
• W3085262751 creator A5007957984 @default.
• W3085262751 creator A5008549101 @default.
• W3085262751 creator A5008946028 @default.
• W3085262751 creator A5019325551 @default.
• W3085262751 creator A5022126823 @default.
• W3085262751 creator A5024725726 @default.
• W3085262751 creator A5027545207 @default.
• W3085262751 creator A5027545625 @default.
• W3085262751 creator A5036465305 @default.
• W3085262751 creator A5038169777 @default.
• W3085262751 creator A5041423375 @default.
• W3085262751 creator A5046746668 @default.
• W3085262751 creator A5046753596 @default.
• W3085262751 creator A5049550015 @default.
• W3085262751 creator A5052664256 @default.
• W3085262751 creator A5065550886 @default.
• W3085262751 creator A5072475537 @default.
• W3085262751 creator A5086362479 @default.
• W3085262751 creator A5089829213 @default.
• W3085262751 creator A5090955736 @default.
• W3085262751 creator A5091623593 @default.
• W3085262751 date "2020-11-10" @default.
• W3085262751 modified "2023-10-16" @default.
• W3085262751 title "Randomized Controlled Trial of Trastuzumab With or Without Chemotherapy for HER2-Positive Early Breast Cancer in Older Patients" @default.
• W3085262751 cites W1566841485 @default.
• W3085262751 cites W1594438765 @default.
• W3085262751 cites W1707141424 @default.
• W3085262751 cites W1961026612 @default.
• W3085262751 cites W2004139144 @default.
• W3085262751 cites W2011284201 @default.
• W3085262751 cites W2016151714 @default.
• W3085262751 cites W2034414538 @default.
• W3085262751 cites W2045324973 @default.
• W3085262751 cites W2045806344 @default.
• W3085262751 cites W2068205530 @default.
• W3085262751 cites W2095156669 @default.
• W3085262751 cites W2095633632 @default.
• W3085262751 cites W2098775844 @default.
• W3085262751 cites W2101253730 @default.
• W3085262751 cites W2105258029 @default.
• W3085262751 cites W2107601678 @default.
• W3085262751 cites W2123591186 @default.
• W3085262751 cites W2130900820 @default.
• W3085262751 cites W2134119471 @default.
• W3085262751 cites W2136166698 @default.
• W3085262751 cites W2137159389 @default.
• W3085262751 cites W2141393790 @default.
• W3085262751 cites W2143283401 @default.
• W3085262751 cites W2144506947 @default.
• W3085262751 cites W2146384083 @default.
• W3085262751 cites W2149386818 @default.
• W3085262751 cites W2149908785 @default.
• W3085262751 cites W2152647863 @default.
• W3085262751 cites W2159296014 @default.
• W3085262751 cites W2159459001 @default.
• W3085262751 cites W2165709481 @default.
• W3085262751 cites W2169281409 @default.
• W3085262751 cites W2169515690 @default.
• W3085262751 cites W2802741453 @default.
• W3085262751 cites W2804780558 @default.
• W3085262751 cites W2944662988 @default.
• W3085262751 cites W2947541583 @default.
• W3085262751 cites W3013564394 @default.
• W3085262751 cites W4239989216 @default.
• W3085262751 doi "https://doi.org/10.1200/jco.20.00184" @default.
• W3085262751 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32936713" @default.
• W3085262751 hasPublicationYear "2020" @default.
• W3085262751 type Work @default.
• W3085262751 sameAs 3085262751 @default.
• W3085262751 citedByCount "48" @default.
• W3085262751 countsByYear W30852627512020 @default.
• W3085262751 countsByYear W30852627512021 @default.
• W3085262751 countsByYear W30852627512022 @default.
• W3085262751 countsByYear W30852627512023 @default.
• W3085262751 crossrefType "journal-article" @default.
• W3085262751 hasAuthorship W3085262751A5007957984 @default.
• W3085262751 hasAuthorship W3085262751A5008549101 @default.
• W3085262751 hasAuthorship W3085262751A5008946028 @default.
• W3085262751 hasAuthorship W3085262751A5019325551 @default.
• W3085262751 hasAuthorship W3085262751A5022126823 @default.
• W3085262751 hasAuthorship W3085262751A5024725726 @default.
• W3085262751 hasAuthorship W3085262751A5027545207 @default.
• W3085262751 hasAuthorship W3085262751A5027545625 @default.
• W3085262751 hasAuthorship W3085262751A5036465305 @default.
• W3085262751 hasAuthorship W3085262751A5038169777 @default.
• W3085262751 hasAuthorship W3085262751A5041423375 @default.
• W3085262751 hasAuthorship W3085262751A5046746668 @default.
• W3085262751 hasAuthorship W3085262751A5046753596 @default.
• W3085262751 hasAuthorship W3085262751A5049550015 @default.
• W3085262751 hasAuthorship W3085262751A5052664256 @default.
• W3085262751 hasAuthorship W3085262751A5065550886 @default.
• W3085262751 hasAuthorship W3085262751A5072475537 @default.
• W3085262751 hasAuthorship W3085262751A5086362479 @default.
• W3085262751 hasAuthorship W3085262751A5089829213 @default.
• W3085262751 hasAuthorship W3085262751A5090955736 @default.
• W3085262751 hasAuthorship W3085262751A5091623593 @default.

• next